From the Vascular Medicine Section, Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
Circ Res. 2015 Apr 24;116(9):1579-98. doi: 10.1161/CIRCRESAHA.114.303505.
Patients with peripheral artery disease (PAD) are at heightened risk of both systemic cardiovascular adverse events, as well as limb-related morbidity. The optimal management of patients with PAD requires a comprehensive treatment strategy incorporating both lifestyle changes, including smoking cessation and exercise, as well as optimal medical therapy. Pharmacological therapies for patients with PAD are targeted both at modifying broad risk factors for major adverse cardiovascular events, as well as reducing limb-related morbidity. Observational data suggest that indicated pharmacological treatments are greatly underutilized in PAD, underscoring the need for improvements in patient identification and care delivery. Ongoing trials of novel therapies in patients with PAD will further inform pharmacological strategies to reduce both systemic cardiovascular risk and limb-related morbidity.
患有外周动脉疾病（PAD）的患者存在全身性心血管不良事件风险增加，以及肢体相关发病率增加的风险。PAD 患者的最佳治疗需要综合治疗策略，包括生活方式改变，如戒烟和运动，以及最佳的药物治疗。PAD 患者的药物治疗既针对主要心血管不良事件的广泛风险因素的改变，也针对减少肢体相关发病率。观察性数据表明，PAD 中指示性药物治疗的利用率非常低，这突显了需要改进患者识别和护理提供。正在进行的 PAD 患者新型治疗的试验将进一步为降低全身性心血管风险和肢体相关发病率的药物治疗策略提供信息。
